⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 23, 2024HeliyonOpen Access

Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis

Dongmei Huang Jinming Zhang Xiangqian Zheng Ming Gao

View Full Paper

Ask AI

Bookmark

Share

Abstract

Selpercatinib is effective in the treatment of RET-altered medullary thyroid carcinoma (MTC). This study aimed to evaluate the efficacy and safety of selpercatinib in the treatment of patients with RET-altered MTC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huang et al. (2024) studied this question.

synapsesocial.com/papers/68e68bf8b6db643587613b68 https://doi.org/10.1016/j.heliyon.2024.e31681

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of selpercatinib in advanced RET-altered thyroid cancers: A meta-analysis and systematic review.2024
2Selpercatinib – a new option for a precision approach to the treatment of medullary thyroid cancerOriginal Research · 2025 · 1 citations
3Selpercatinib in non-MTC, RET-mutated tumors: Efficacy in MEN-associated and other tumors.2024 · 2 citations
4Real-world clinical responses to selpercatinib in RET M918T-mutant medullary thyroid carcinomaCase Report · 2026
5Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer2024 · 27 citations